Targeting cancer’s energy factory: Breakthrough nanotherapy fights hardest-to-treat breast tumors
Peer-Reviewed Publication
Updates every hour. Last Updated: 12-Jul-2025 00:11 ET (12-Jul-2025 04:11 GMT/UTC)
Scientists have uncovered a key driver of triple-negative breast cancer (TNBC) progression—a metabolic enzyme called LPCAT1—and developed a targeted nanoparticle therapy to block it. By silencing LPCAT1, the treatment disrupts cancer cell energy production and halts tumor growth and lung metastasis in TNBC, the most aggressive breast cancer subtype. This breakthrough offers a promising new strategy for treating advanced TNBC, which currently has limited therapeutic options.
Researchers from the Stem Cells and Cancer team at the Josep Carreras Leukaemia Research Institute and the Hospital del Mar Research Institute have developed a method to confidently produce blood cell precursors from stem cells in mice, by activating a set of seven key genes in the laboratory. The team, led by Dr. Anna Bigas, takes a step forward towards the production of precursor cells able to restore the bone marrow of blood cancer patients, in a successful example of regenerative medicine.
Research on diabetes, multiple myeloma, metastatic colorectal cancer, biomarkers for immunotherapy responses, heart health after pediatric cancer and a potential new treatment for chronic myeloid leukemia are highlighted in this spotlight
Registration opens today for the 67th American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held at the Moscone Center in San Francisco, September 27 to October 1, 2025. Led by ASTRO President Sameer Keole, MD, FASTRO, the conference is centered around the theme of “Rediscovering Radiation Medicine and Exploring New Indications” and is expected to attract up to 10,000 oncologists, clinicians, researchers and other health care professionals from around the globe. ASTRO news briefings will feature noteworthy and high-impact research presented at the meeting; briefing details will be announced in early September.
Scientists at St. Jude Children’s Research Hospital showed how inheriting a deficient ELP1 gene increases the risk of SHH-driven pediatric medulloblastoma and further revealed that MDM2 inhibitors can help stop it.